Rarity & Risk of Secondary Hematologic Neoplasms after CAR T-cell Therapies

Mark P Hamilton1, Ash A Alizadeh2

  • 1Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA; Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA 94305, USA; Division of Blood and Marrow Transplantation and Cellular Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA.

Abstract

No abstract available in PubMed .